Search clinical trials for: Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Thymoglobulin

Total 2187 results

Massachusetts General Hospital

Recruiting

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

Renal Failure

United States
Masonic Cancer Center, University of Minnesota

Terminated

Stem Cell Transplantation for Fanconi Anemia

Fanconi Anemia

United States
The Korean Society of Pediatric Hematology Oncology

Unknown

Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)

Anemia, Aplastic

Korea, Republic of
Massachusetts General Hospital

Completed

Renal Allograft Tolerance Through Mixed Chimerism

End Stage Renal Disease

United States
The Korean Society of Pediatric Hematology Oncology

Unknown

Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)

Aplastic Anemia

Korea, Republic of
Memorial Sloan Kettering Cancer Center

Active, not recruiting

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Myeloid Diseases

United States
Gruppo Italiano Studio Linfomi

Completed

Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab

Follicular Lymphoma

Italy
Nantes University Hospital

Completed

Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies (ITT 08-01)

Hematological Malignancies

France
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia

Leukemia

United States
German CLL Study Group

Terminated

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia

Prolymphocytic Leukemia

Germany
Institute of Cancer Research, United Kingdom
Australasian Leukaemia and Lymphoma Group

Completed

Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma

Lymphoma

Australia, United Kingdom
University of Illinois at Chicago

Recruiting

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Sickle Cell Disease

United States
Hoffmann-La Roche

Completed

CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy

Lymphocytic Leukemia, Chronic

Austria
Asociacion Espanola de Hematologia y Hemoterapia

Completed

Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma

Non Hodgkin Lymphoma

Spain
City of Hope Medical Center

Withdrawn

Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia

Severe Aplastic Anemia
Nantes University Hospital

Not yet recruiting

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (CY-MET-RIC)

Hematologic Malignancy | Graft Versus Host Disease
Technical University of Munich

Unknown

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

Lymphoma

Germany
University Hospital Tuebingen

Terminated

Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia (CD3/CD19 Haplo)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

Germany
Institut Paoli-Calmettes
Agence de La Biomédecine

Completed

Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases (BX-PK)

Hematological Diseases

France
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Northside Hospital, Inc.

Recruiting

Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

Severe Aplastic Anemia

United States
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

Leukemia, Myelocytic, Acute

United States
University of Liege
Belgian Hematological Society

Recruiting

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning (HLA)

Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Non Hodgkin Lymphoma | Myeloproliferative Disorder | Chronic Lymphoid Leukemia | Acute Myeloid Leukemia in Remission | Myeloproliferative Syndrome | Chronic Myeloid Leukemia in Remission | Acute Lymphoid Leukemia in Remission

Belgium
Nantes University Hospital

Completed

Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens (FB4-PEDIA)

Hematologic Malignancy

France
Porteus, Matthew, MD

Recruiting

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

Fanconi Anemia

United States
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Allogeneic Transplant in HIV Patients (BMT CTN 0903)

Lymphoma | Leukemia | HIV

United States
French Innovative Leukemia Organisation

Completed

Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP

Leukemia

France
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL (ZFCR/ZBR)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Newly Diagnosed

China
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Nantes University Hospital

Terminated

Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC (CYRIC)

Graft Versus Host Disease

France
Massachusetts General Hospital

Terminated

Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant (RLI)

Multiple Myeloma | Hodgkin Disease | Non Hodgkin's Lymphoma

United States
University Hospital, Clermont-Ferrand

Unknown

Allogeneic Hematopoietic Stem Cell Transplantation (RICE)

Hematologic Neoplasms | Solid Tumors

France
Massachusetts General Hospital

Completed

Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)

Renal Insufficiency | Kidney Failure, Chronic

United States
The Korean Society of Pediatric Hematology Oncology

Completed

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)

Wiskott-Aldrich Syndrome

Korea, Republic of
Hackensack Meridian Health
Celgene Corporation

Completed

Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide (FCR)

Chronic Lymphocytic Leukemia (CLL)

United States
The Korean Society of Pediatric Hematology Oncology

Unknown

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML

Acute Myeloid Leukemia

Korea, Republic of
A.O. Ospedale Papa Giovanni XXIII

Completed

Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) (FCD-R)

Post-transplant Lymphoproliferative Disease (PTLD) | Non Burkitt

Italy
Cancer Trials Ireland

Completed

CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

Leukemia

Ireland
Memorial Sloan Kettering Cancer Center

Terminated

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML) | Acute Lymphoid Leukemia (ALL)

United States
Naoyuki G. Saito, M.D., Ph.D.

Withdrawn

A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia

United States
Cancer Research UK

Completed

Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Leukemia

United Kingdom
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; SWOG Cancer Research...

Completed

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Canada
M.D. Anderson Cancer Center

Completed

Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia

Aplastic Anemia

United States
Emory University

Completed

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow (TRANSFORM)

Sickle Cell Disease

United States
Zhejiang University
Hangzhou Qihan Biotech Co.,Ltd.

Recruiting

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Lymphoma | Leukemia

United States
M.D. Anderson Cancer Center

Completed

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

Myelofibrosis

United States
Genta Incorporated

Completed

Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

Follicular Lymphoma

Italy, Israel, Germany, France, Greece, Spain, Switzerland
The First Affiliated Hospital of Soochow University

Recruiting

TFBC Combined With UCBT in the Treatment of High-risk Malignant Hematological Diseases

Hematopoietic Stem Cell Transplantation | Malignant Hematological Diseases

China

3

Subscribe